Journal Mobile Options
Table of Contents
Vol. 57, No. 2, 1999
Issue release date: August 1999

Dose Intensification of Platinum Compounds with Glutathione Protection as Induction Chemotherapy for Advanced Ovarian Carcinoma

Böhm S. · Oriana S. · Spatti G. · Di Re F. · Breasciani G. · Pirovano C. · Grosso I. · Martini C. · Caraceni A. · Pilotti S. · Zunino F.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Based on previous clinical experience indicating the tolerability and efficacy of high-dose cisplatin with glutathione protection in the treatment of advanced ovarian cancer, this study was undertaken to explore the efficacy and feasibility of an alternative high-dose, platinum-based approach including a combination of high-dose cisplatin plus carboplatin as induction chemotherapy of advanced ovarian carcinoma and intervention surgery. Fifty consecutive eligible patients with untreated stage III or IV epithelial ovarian cancer received 40 mg/m2 cisplatin daily on days 1–4 and 160 mg/m2 carboplatin on day 5. The cycle was repeated after 28 days. Patients received glutathione (2,500 mg) before each cisplatin or carboplatin administration and standard intravenous hydration. After 2 courses of induction chemotherapy, the patients underwent surgical reevaluation with debulking, when possible, followed by a further 3 cycles of 120 mg/m2 cisplatin (i.e. 40 mg/m2 daily for 3 consecutive days plus 600 mg/m2 cyclophosphamide on day 3) except in instances of lack of response. All eligible patients were assessed for response and toxicity. The toxicity was moderate with lack of significant nephrotoxicity. Neurotoxicity and ototoxicity were acceptable and in no patient was treatment discontinued for those toxic effects. Myelotoxicity was somewhat more severe than that observed with our previous study with high-dose cisplatin and probably related to the addition of carboplatin. Of the 40 responsive patients, 23 (46%) had a pathological complete response and 4 (8%) had a clinical complete response (without second-look laparotomy). The efficacy of the present protocol was also documented by overall survival (median survival >48 months), which appeared to be better than expected with the current therapy in this group with advanced/bulky disease. The impressive efficacy suggests a possible contribution of reduced glutathione itself in improving the outcome, as supported by preclinical studies. The results of this study should be placed in context with current platinum-based therapy including paclitaxel.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hacker NF, van der Burg MEL: Debulking and intervention surgery. Ann Oncol 1993;4:17–22.

    External Resources

  2. Van der Burg MEL, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332:629–634.
  3. Friedlander ML, Dembo AJ: Prognostic factors in ovarian cancer. Semin Oncol 1991;18:205–212.
  4. Sandercock J, Parmar MKB, Torri V: First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence. Br J Cancer 1998;78:1471–1478.

    External Resources

  5. Vermorken JB, Hoekman K: Chemotherapy for gynecologic malignancies. Curr Opin Oncol 1995;7:457–465.
  6. Ozols RF: Cisplatin dose intensity. Semin Oncol 1989;16:22–30.
  7. Di Re F, Bohm S, Oriana S, Spatti GB, Pirovano C, Tedeschi M, Zunino F: High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol 1993;4:55–61.
  8. Thigpen JT, Bertelsen K, Eisenhauer EA, Hacker NF, Lund B, Sessa C: Long-term follow-up of patients with advanced ovarian carcinoma treated with chemotherapy. Ann Oncol 1993;4:35–40.
  9. Gershenson DM, Morris M, Burke TW, Lavenback C, Kavanagh JJ, Fromm GL, Silva EG, Warner D, Wharton JT: Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer. Gynecol Oncol 1995;58:349–355.
  10. Alberts DS: Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 1995;22:88–90.
  11. Thigpen JT: Dose-intensity in ovarian carcinoma: Hold, enough? J Clin Oncol 1997;15:1291–1293.
  12. Kaye SB, Lewis CR, Paul J, Duncan ID, Gordon HK, Kitchener HC, Cruickshank DJ, Atkinson RJ, Soukop M, Rankin EM, Cassidy J, Davis JA, Reed NS, Crawford SM, MacLean A, Swapp GA, Sarkar TK, Kennedy JH, Symonds RP: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992;340:329–333.
  13. Zunino F, Pratesi G, Micheloni A, Cavalleti E, Sala F, Tofanetti O: Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact 1989;70:89–101.
  14. Tedeschi M, Bohm S, Di Re F, Oriana S, Spatti GB, Tognella S, Zunino F: Glutathione and detoxification. Cancer Treat Rev 1990;17:203–208.

    External Resources

  15. Makatsoris T, Seiden MV: High-dose therapy for ovarian carcinoma. Oncologist 1997;2:330–339.

    External Resources

  16. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani G, Spatti G, Zunino F: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996;56:689–693.
  17. Lavarino C, Delia D, Di Palma S, Zunino F, Pilotti S: p53 in drug resistance in ovarian cancer. Lancet 1997;349:1556.
  18. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1–6.
  19. Smyth JF, Bowman A, Perren T, Wilkinson P, Prescott RJ, Quinn KJ, Tedeschi M: Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol 1997;8:569–573.

    External Resources

  20. Strauss G, Lund B, Hansen M, Hansen HH: Phase II trial of high-dose cisplatin plus ifosfamide as first-line followed by carboplatin as second-line treatment in epithelial ovarian carcinoma. Gynecol Oncol 1997;66:66–70.

    External Resources

  21. Dedon PC, Borch RF: Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1987;36:1955–1964.
  22. Perego P, Paolicchi A, Tongiani R, Pompella A, Tonarelli P, Carenini N, Romanelli S, Zunino F: The cell-specific anti-proliferative effect of reduced glutathione is mediated by γ-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions. Int J Cancer 1997;71:246–250.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50